Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

VP025

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The deficit in long-term potentiation induced by chronic administration of amyloid-β is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025
Amyloid-beta (Abeta) peptides, the primary component of the amyloid plaques in Alzheimer's disease (AD), exert profound effects… Expand
  • figure 1
  • figure 2
2009
2009
A Novel Phospholipid-Based Drug Formulation, VP025, Modulates Age- and LPS-Induced Microglial Activity in the Rat
Background: A common change that occurs with age in the central nervous system is an increase in microglial-associated… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
Neuroprotective effects of novel phosphatidylglycerol‐based phospholipids in the 6‐hydroxydopamine model of Parkinson's disease
Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating… Expand
2008
2008
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson’s disease
Failure of the ubiquitin-proteasome system to degrade abnormal proteins may underlie the accumulation of alpha-synuclein and… Expand
2008
2008
Analysis of the effects of amyloid-beta in rat brain : effect of treatment with a novel anti-inflammatory agent VP025
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE